No profile data available.
Halozyme Therapeutics, Inc. (HALO) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 423 full-time employees.
It reported revenue of $1.40 billion for fiscal year 2025, up 37.6% from fiscal year 2024, and net income of $316.89 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $481.00 million, up 47.7% from a year before. United States was its largest region in fiscal year 2025, with 59% of revenue. Its market capitalization was $12.53 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Halozyme Therapeutics reported $1.40 billion in revenue for fiscal year 2025, up 37.6% from $1.02 billion in fiscal year 2024. In Q2 2026 revenue was $481.00 million.
United States: 59% of revenue by region in fiscal year 2025, followed by Switzerland (20%).
$12.53 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Revolution Medicines, Inc. (RVMD), Exelixis, Inc. (EXEL), Summit Therapeutics Inc. (SMMT), ImmunityBio, Inc. (IBRX).